Cargando…
High Density Lipoprotein and Its Precursor Protein Apolipoprotein A1 as Potential Therapeutics to Prevent Anthracycline Associated Cardiotoxicity
Cardiovascular disease and cancer are the leading causes of death in developed societies. Despite their effectiveness, many cancer therapies exhibit deleterious cardiovascular side effects such as cardiotoxicity and heart failure. The cardiotoxic effects of anthracyclines such as doxorubicin are the...
Autores principales: | Kluck, George E. G., Durham, Kristina K., Yoo, Jeong-Ah, Trigatti, Bernardo L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7198830/ https://www.ncbi.nlm.nih.gov/pubmed/32411725 http://dx.doi.org/10.3389/fcvm.2020.00065 |
Ejemplares similares
-
Novel Therapeutics for Anthracycline Induced Cardiotoxicity
por: Vuong, Jacqueline T., et al.
Publicado: (2022) -
Cardiotoxicity of Anthracyclines
por: Cardinale, Daniela, et al.
Publicado: (2020) -
Genetics of Anthracycline-Associated Cardiotoxicity
por: Al-Otaibi, Talal Khalid, et al.
Publicado: (2022) -
Risk Factors for Anthracycline-Induced Cardiotoxicity
por: Qiu, Shuo, et al.
Publicado: (2021) -
Cardiac MRI assessment of anthracycline-induced cardiotoxicity
por: Mabudian, Leila, et al.
Publicado: (2022)